U.S. markets close in 13 minutes

Puma Biotechnology, Inc. (PBYI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.12+0.30 (+4.40%)
As of 3:47PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close6.82
Open6.87
Bid7.14 x 3100
Ask7.17 x 900
Day's Range6.85 - 7.24
52 Week Range6.48 - 14.14
Volume202,402
Avg. Volume413,492
Market Cap290.346M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Puma Biotechnology Inc
    Analyst Report: Seagen Inc.Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer and Tukysa for breast cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more